NMPA (China) approves Tecvayli (teclistamab) for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior lines of treatment
Johnson & Johnson's Tecvayli has secured approval from China's National Medical Products Administration (NMPA). In China, the drug is approved for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior lines of treatment
The drug is the first bispecific antibody targeting BCMA and CD3 to treat relapsed or refractory multiple myeloma in China, J&J said in a Chinese-language release. It's J&J's fourth drug for multiple myeloma to gain approval in the country.
In a clinical trial, Chinese patients with multiple myeloma who had tried at least three other options experienced an overall response rate of 76.9% on the antibody therapy.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins